stephane BREZILLON

Dr. stephane BREZILLON

UMR CNRS / URCA n°7369, Matrice Extracellulaire et Dynamique Cellulaire (MEDyC), Laboratoire de Biochimie Médicale et de Biologie Moléculaire, Faculté de Médecine, 51 Rue Cognacq Jay, F51095 Reims CEDEX, France

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2020 in Seminars in Cancer Biology
Verified
Journal Article
Closed access
KKKonstantina Karamanou
Konstantina Karamanou
MFMarco Franchi
Marco Franchi
DVDemitrios Vynios
Demitrios Vynios
SBstephane BREZILLON
stephane BREZILLON

25 February 2013 in The FEBS Journal
Verified
Journal Article
Open access
PDF file
SBstephane BREZILLON
stephane BREZILLON
KPKatarzyna Pietraszek-Gremplewicz
Katarzyna Pietraszek-Gremplewicz
FMFrançois‐Xavier Maquart
François‐Xavier Maquart
YWYanusz Wegrowski
Yanusz Wegrowski
Lumican is a member of the small leucine‐rich proteoglycan family. It is present in numerous extracellular matrices of different tissues, such as muscle, cartilage, and cornea. In skin, lumican is present as a glycoprotein. It plays a critical role in collagen fibrillogenesis, as shown by knocking out of its gene in mice. A direct link between lumican expression and melanoma progression and metastasis has been demonstrated. Lumican was shown to impede tumour cell migration and invasion by directly interacting with the α2β1 integrin. In addition, an active sequence of the lumican core protein, called lumcorin, was identified as being responsible for inhibition of melanoma cell migration. Lumican was also shown to exert angiostatic properties by downregulating the proteolytic activity associated with endothelial cell membranes, particularly matrix metalloproteinase (MMP)‐14 and MMP‐9. Globally, lumican appears to be a potent agent for inhibiting tumour progression rather than tumorigenesis. However, progressive changes in proteoglycans occur in the tumour environment. The complexity and diversity of proteoglycan structure might be responsible for a variety of functions that regulate cell behaviour. Through their core protein and their glycosaminoglycan chains, proteoglycans can interact with growth factors and chemokines. These interactions affect cell signalling, motility, adhesion, growth, and apoptosis. This review summarizes recent data concerning lumican control of tumour progression in different cancers, with a particular focus on its interactions with MMPs and integrins. Its potential therapeutic implications are discussed.

1 April 2018 in Advanced Drug Delivery Reviews
Verified
Journal Article
Closed access
KKKonstantina Karamanou
Konstantina Karamanou
GPGwenn Perrot
Gwenn Perrot
FMFrancois-Xavier Maquart
Francois-Xavier Maquart
SBstephane BREZILLON
stephane BREZILLON

23 March 2017 in Scientific Reports
Verified
Journal Article
Open access
PDF file
KKKonstantina Karamanou
Konstantina Karamanou
MFMarco Franchi
Marco Franchi
Zoi PiperigkouZoi Piperigkou
Zoi Piperigkou
CPCorinne Perreau
Corinne Perreau
FMFrancois-Xavier Maquart
Francois-Xavier Maquart
SBstephane BREZILLON
stephane BREZILLON
Lumican is a small leucine-rich proteoglycan that has been shown to contribute in several physiological processes, but also to exert anticancer activity. On the other hand, it has been recently shown that knockdown of the estrogen receptor α (ERα) in low invasive MCF-7 (ERα+) breast cancer cells and the suppression of ERβ in highly aggressive MDA-MB-231 (ERβ+) cells significantly alter the functional properties of breast cancer cells and the gene expression profile of matrix macromolecules related to cancer progression and cell morphology. In this report, we evaluated the effects of lumican in respect to the ERs-associated breast cancer cell behaviour, before and after suppression of ERs, using scanning electron and confocal microscopies, qPCR and functional assays. Our data pinpointed that lumican significantly attenuated cell functional properties, including proliferation, migration and invasion. Furthermore, it modified cell morphology, inducing cell-cell junctions, evoked EMT/MET reprogramming and suppressed the expression of major matrix effectors (matrix metalloproteinases and EGFR) implicated in breast cancer progression. The effects of lumican were found to be related to the type of breast cancer cells and the ERα/β type. These data support the anticancer activity of lumican and open a new area for the pharmacological targeting of the invasive breast cancer.

1 July 2007 in Clinical and Experimental Dermatology
Verified
Journal Article
Closed access
PDF file
SBstephane BREZILLON
stephane BREZILLON
LVL. Venteo
L. Venteo
LRL. Ramont
L. Ramont
MDM.-F. D'Onofrio
M.-F. D'Onofrio
CPC. Perreau
C. Perreau
YWY. Wegrowski
Y. Wegrowski

1 September 2009 in Cancer Letters
Verified
Journal Article
Closed access
SBstephane BREZILLON
stephane BREZILLON
ARAgata Radwanska
Agata Radwanska
CZCedric Zeltz
Cedric Zeltz
AMAndrzej Malkowski
Andrzej Malkowski
DPDominique Ploton
Dominique Ploton
YWYanusz Wegrowski
Yanusz Wegrowski